Jump to content

Diagnostics

The latest articles, press releases and dossiers on diagnostics in Baden-Württemberg

  • Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB - 24/04/2020

    Every year, around 11 million people die of sepsis (blood poisoning) caused by microorganisms or microbial residues, known as pyrogens, entering the bloodstream. The smallest amounts can trigger fever. Researchers from the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart have developed a pyrogen test that does not require a laboratory and is not tested on animals. It is expected to be placed on the market soon.

  • Bioinspired technologies - 03/04/2020

    The CRISPR-Cas gene-editing technology is one of the most important developments in molecular biology in recent years. It utilises molecular scissors with which nucleic acids can be cut and edited almost arbitrarily. Researchers in Freiburg, Germany have now successfully used the technology for diagnostic purposes. They are currently working intensively on expanding the system to enable it to detect genome sequences of the novel SARS-CoV-2 virus.

  • Dossier - 06/12/2019

    People have 1.3 times more microorganisms than body cells. This microbial community influences how we digest our food, how active our immune system is, as well as whether we tend to be more anxious or curious. A number of diseases have also been shown to be associated with a disturbed microbiome. Researchers still have a long way to go before the knowledge acquired can be used for developing therapies.

  • Article - 22/10/2019

    After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.

  • Vision Zero in oncology - 02/09/2019

    While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.

  • Article - 16/04/2019

    Liquid biopsy, the analysis of cancer biomarkers and circulating tumour cells in body fluids such as blood, is revolutionising the diagnosis and monitoring of cancer. It has also been possible to expand circulating tumour cells from the blood under laboratory conditions. It is expected that in the future, liquid biopsy will be able to precisely characterise tumour cells at every stage of a cancer.

  • Article - 07/02/2019

    Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.

  • Dossier - 28/08/2018

    Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.

Website address: https://www.gesundheitsindustrie-bw.de/en/article/diagnostics